Bluebird Bio and Xcellbio have entered into an agreement to support the commercialization of sickle cell gene therapy ...

Doctors and researchers at the University of Nebraska Medical Center are hoping to bring a different therapy that uses a ...

AB Science will be granted a patent, valid through 2040, covering the medical use of masitinib as a treatment for sickle cell ...

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with ...

This month, 21-year-old Sebastien Beauzile became the first man in New York history to be cured of sickle cell anemia, a genetic blood disorder, thanks to a new form of gene therapy. “ ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with ...

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL ...

the first CRISPR/Cas9 gene-editing therapy in the UAE. This achievement opens new horizons and offers innovative treatment for patients suffering from sickle cell disease (SCD) and transfusion ...

Gene editing technologies have cemented their place as a valued method in the biological toolkit used by researchers around the globe.